Target intelligence / Profile preview

Neutrophil elastase (NE) (ELANE)

Target
ELANE
Molecular classification
Enzyme, Serine protease, Peptidase S1 family
01

Overview

Neutrophil elastase (NE) is a potent serine protease primarily stored within the azurophilic granules of neutrophils and released during inflammatory responses. Its primary biological function involves the degradation of foreign proteins and the destruction of pathogens, contributing significantly to the innate immune response and the formation of neutrophil extracellular traps (NETs). Under physiological conditions, its activity is tightly regulated by endogenous inhibitors like alpha-1 antitrypsin to prevent collateral damage to host tissues. However, an imbalance between NE and its inhibitors leads to excessive proteolysis of extracellular matrix components, such as elastin and collagen, resulting in significant tissue destruction. This pathological process is a hallmark of several chronic and acute respiratory diseases, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and acute respiratory distress syndrome (ARDS). Consequently, NE is a major therapeutic target, with various synthetic inhibitors like sivelestat and alvelestat developed to mitigate inflammatory tissue damage. Therapeutic challenges include maintaining the protease-antiprotease balance without compromising the patient's ability to clear infections.

Other names
Granulocyte elastaseLeukocyte elastasePolymorphonuclear leukocyte elastasePMN elastaseElastase-2MedullasinBone marrow serine proteaseHuman leukocyte elastase (HLE)Human neutrophil elastase (HNE)
02

Mechanism of action

Inhibition of proteolytic activity through competitive, non-competitive, or allosteric binding to the enzyme's active site or regulatory domains.

03

Biological functions

Immune responseProteolysisAntimicrobial activityExtracellular matrix degradationNeutrophil extracellular trap (NET) formationTissue remodelingBlood coagulation
04

Disease associations

Chronic obstructive pulmonary disease (COPD)EmphysemaCystic fibrosisBronchiectasisAcute respiratory distress syndrome (ARDS)Alpha-1 antitrypsin deficiencyCyclic neutropeniaSevere congenital neutropeniaCancer metastasisRheumatoid arthritisSepsis
05

Safety considerations

Risk of impaired host defense against bacterial and fungal infectionsPotential off-target inhibition of other serine proteasesStability and bioavailability challenges for synthetic inhibitorsPotential for immunosuppression
06

Interacting drugs

Sivelestat

5 more in the full profile.

07

Biomarkers

Plasma neutrophil elastase levelsNeutrophil elastase-alpha1-antitrypsin complexesSputum neutrophil elastase activityDesmosineIsodesmosine

Beyond the preview

Go deeper on Neutrophil elastase (NE) (ELANE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neutrophil elastase (NE) (ELANE).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call